Hirsutism surgery

Jump to navigation Jump to search

Hirsutism Microchapters


Patient Information


Historical Perspective




Differentiating Hirsutism from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography or Ultrasonography


Medical Therapy

Pharmacological therapy
Non-pharmacological therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hirsutism surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hirsutism surgery

CDC on Hirsutism surgery

Hirsutism surgery in the news

Blogs on Hirsutism surgery

Directions to Hospitals Treating Hirsutism surgery

Risk calculators and risk factors for Hirsutism surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2], Rasam Hajiannasab M.D.[3], Eiman Ghaffarpasand, M.D. [4]


The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either ovarian tumor, adrenal tumor, perimenopausal or postmenopausal women with severe hyperandrogenism who are candidated for oophorectomy, or bariatric surgery for severe obesity.



  1. 1.0 1.1 Franks, Stephen (2012). "The investigation and management of hirsutism". Journal of Family Planning and Reproductive Health Care. 38 (3): 182–186. doi:10.1136/jfprhc-2011-100175. ISSN 1471-1893.
  2. Souto SB, Baptista PV, Braga DC, Carvalho D (2014). "Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism". Arq Bras Endocrinol Metabol. 58 (1): 68–75. PMID 24728167.
  3. Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B; et al. (2010). "Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature". Exp Clin Endocrinol Diabetes. 118 (5): 291–7. doi:10.1055/s-0029-1225351. PMID 20198556.
  4. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012). "Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group". Fertil. Steril. 97 (1): 28–38.e25. doi:10.1016/j.fertnstert.2011.09.024. PMID 22153789.
  5. Spritzer PM (2014). "Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances". Arq Bras Endocrinol Metabol. 58 (2): 182–7. PMID 24830595.